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Serum alpha-fetoprotein (AFP) is a glycoprotein which has been
reported to consist of 591 amino acids and one asparagine-linked
bi-antennary complex-type sugar chain (Tarelli et al, 1992;
Ferranti et al, 1995). The carbohydrate moiety of AFP exhibits
microheterogeneity, as revealed by isoelectric focusing (Alpert
et al, 1972; Burditt et al, 1994; Johnson et al, 1995) and lectin
electrophoretic (Taketa et al, 1993; Shimizu et al, 1996) tech-
niques. The sugar chain of AFP, purified from the ascitic fluid of a
patient with hepatocellular carcinoma (HCC), consisted of a single
N-linked sugar chain of the bi-antennary complex-type with a
degree of heterogeneity based on differing degrees of terminal
sialylation and proximal fucosylation (Figure 1) (Yoshima et al,
1980). This basic structure has been confirmed by mass spectro-
metric analysis of AFP derived from the hepatoblastoma cell line
Hep G2 (Tarelli et al, 1992; Ferranti et al, 1995), and by paper
electrophoretic and chromatographic analysis of pooled human-
cord serum AFP at term pregnancy (Yamashita et al, 1993).
However, the abundance of the AFP isoforms differed in the two
sources of materials (Yamashita et al, 1993; Ferranti et al, 1995).
Largely because of the extremely small amounts of protein avail-
able, there has been very little data on human serum AFP in
patients with HCC or non-seminomatous germ cell tumours
(NSGCT).
Measurement of serum AFP (reference range < 10 ng ml–1) is
used as a serological tumour marker in HCC (Johnson et al, 1978;
Sheu et al, 1985; Nomura et al, 1989) and NSGCT (Lange and
Fralay, 1977; Javadpour, 1980; Kay et al, 1987; Nichols et al,
1990). About 80% of patients with HCC will have levels above the
reference range (Johnson et al, 1978; Sheu et al, 1985; Nomura
et al, 1989). A serum concentration of greater than 500 ng ml–1, in
an HCC high incidence area and in the appropriate clinical setting,
is almost diagnostic of HCC. However, modestly raised levels of
AFP (10–500 ng ml–1) may also be detected in non-malignant
chronic liver diseases, thereby decreasing the specificity of the
AFP test for HCC (Johnson et al, 1978; Okuda, 1986; Lok and
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Lai, 1989). This poses an important clinical problem since most
HCCs arise in patients with co-existing chronic liver disease
(Kew and Popper, 1984; Johnson and Williams, 1987).
Several attempts have been made to identify a ‘tumour-specific’
glycoform, aiming thereby to improve the specificity of AFP as a
diagnostic test for HCC. Previously the most successful approach
in identifying tumour-specific isoforms has been based on the
difference in their binding affinity to various lectins, particularly
lentil lectin and concanavalin A (ConA). Indeed, differences in
binding patterns of AFP of different origins were found (Smith
and Kelleher, 1980; Buamah et al, 1986; Du et al, 1991). More
recently, isoelectric focusing (IEF) has been used to identify
directly isoforms of AFP. The AFP+II (band +II) and AFP+III
(band +III) appear highly specific for HCC (Burditt et al, 1994; Ho
et al, 1996) and NSGCT (Johnson et al, 1995) respectively. A
unique IEF pattern is also found for the AFP which arises in
patients with chronic liver disease without any evidence of malig-
nancy (Ho et al, 1996; Johnson et al, 1997). Preliminary studies
suggest that this approach may allow early, even preclinical,
diagnosis of HCC in high-risk patients (Johnson et al, 1997).
In this study we have separated the sugar chains of serum AFP
from patients with NSGCT and HCC by high-performance liquid
chromatography (HPLC), resulting in the identification of 11
different glycans. Their compositions have been determined using
sequential exoglycosidase digestion followed by chromatography
or matrix-assisted laser desorption ionization in time-of-flight
(MALDI-TOF) mass spectrometry. This study provides the basis
for evaluating the specificity of the IEF method for separating the
isoforms of AFP and for developing a routine assay for AFP with
increased specificity for the detection of NSGCT and HCC.
MATERIALS AND METHODS
Sera were collected from two patients with histologically
confirmed HCC with serum AFP levels of 1 513 000 and
1 486 000 ng ml–1, and two patients with histologically confirmed
NSGCT with serum AFP levels of 14 000 and 17 000 ng ml–1. The
concentration of serum AFP was assayed by a microparticle
enzyme immunoassay (MEIA, Abbott Laboratories, IL, USA).
Sera were stored at –70°C until further analysis, or purification of
AFP.
Purification of AFP by one-step affinity
chromatography
Rabbit anti-human AFP (Dako, Denmark) was coupled to CNBr-
activated Sepharose 4B (Pharmacia Biotech, Uppsala, Sweden),
overnight at 4°C in coupling buffer (0.2 M NaHCO3, 0.5 M sodium
chloride (NaCl), pH 8.6). Non-specific binding sites were blocked
using 0.2 M glycine, pH 8.0 over 2 h at room temperature.
Uncoupled antibody was removed by extensively washing the gel
alternately with acetate buffer (0.1 M sodium acetate, 0.5 M NaCl,
pH 4.0) and the coupling buffer. A column containing 40 ml of
coupled gel was equilibrated with phosphate-buffered saline (PBS,
10 mM sodium phosphate, 100 mM NaCl, pH 6.8). The sample to
be purified (approximately 400 ug AFP per 40 ml gel) was applied
and run at a flow rate of 1 ml min–1 for 30 min. The flow was then
interrupted for approximately 2.5 h in order to allow for optimal
binding. The column was then washed with approximately 100 ml
of PBS. Bound AFP was eluted with 100 ml of 3 M NaSCN,
pH 6.4. The eluate was dialysed in PBS overnight at 4°C. The
resulting dialysate was concentrated to approximately 1 ml using a
Centriprep 30 concentrator (Amicon, MA, USA). The ‘total’ AFP
concentration was determined as previously described. The purity
of the final AFP preparation was regarded as acceptable when
only one single band, with a molecular weight of 69 kDa, was
visualized on a sodium dodecyl sulphate polyacrylamide gel elec-
trophoresis (SDS-PAGE) gel using silver staining.
Glycan analysis of purified AFP in HCC and NSGCT
Glycans were released from an aliquot (~2 µg) of salt-free
(dialysed) AFP, purified from each of the two HCC patients and
two NSGCT patients, by hydrazinolysis as described previously
(Patel et al, 1993). The released glycans were fluorescently
labelled at the reducing terminal with 2-aminobenzamide (2-AB)
by a reductive amination reaction (Bigge et al, 1995).
2-AB labelled glycan profiling was performed on a Hypersil
C18 HPLC column (250 ´ 4.6 mm i.d.). The HPLC system
consisted of a Rheodyne manual injector, Gilson 305 and 306
pumps, Gilson 805 manometric module and Gilson 811C dynamic
mixer. The 2-AB labelled glycans were eluted from the column
using gradient conditions by an eluent consisting of 40 mM ammo-
nium acetate, pH 6.0 and 50 mM ammonium acetate, pH 6.0
containing 8% acetonitrile at a flow rate of 0.5 ml min–1, as pre-
viously reported (Patel et al, 1993). Detection of 2-AB labelled
glycans was achieved on a Jasco FP-920 fluorimeter (lex = 330,
lem = 420 nm) and data were collected on a PE Nelson 900 Series
Interface for subsequent computer-assisted analysis (Oxford
GlycoSciences Data Analysis software) and simultaneously on a
Kipp and Zonen chart recorder. When fractions were required, the
eluate from the fluorimeter was connected to a Gilson 203 fraction
collector.
To determine the structure, 2-AB labelled glycans were taken
to dryness under reduced pressure (Savant) and treated with
Athrobacter ureafaciens sialidase (100 mU in 30 µl reconstitution
buffer),  Streptococcus pneumoniae b-galactosidase (10 mU in
50 µl), Bovine testes b-galactosidase (100 mU in 30 µl), or
Streptococcus pneumoniae b-N-acetylhexosaminidase (30 mU in
30 µl) at 37°C for 16 h. The digests were purified by passing them
through a column containing 0.15 ml AG X16 triethylammonium
form and 0.15 ml AG X8 acetate form and eluting with 2 ml
HPLC grade water.
Gel filtration chromatography of neutral or desialyated 2-AB
labelled glycans was performed on an Oxford GlycoSciences
GlycoSequencerTM at a flow rate of 160 µl min–1 in accordance
with the manufacturer’s instruction. A GlycoSep H HPLC column
(100  ´ 3 mm i.d., Oxford GlycoSciences) was connected to a
Gilson HPLC system as previously described and 2-AB labelled
monosaccharides were eluted with gradient conditions by an
eluent consisting of acetonitrile and 0.1% aqueous trifluroacetic
acid containing 5% acetonitrile as previously reported (Bigge et al,
1995).
The molecular weight of 2-AB labelled glycans from AFP
were determined by MALDI-TOF mass spectrometry using a
PerSeptive Biosystems Voyager Elite time-of-flight mass spec-
trometer. Spectra were acquired with delayed extraction (100 nS)
and an acceleration voltage of 20 kV. External calibration against a
mixture of peptides was used. The matrix solution of alpha-cyano-
4-hydroxycinnamic acid (Hewlett-Packard) was mixed with an
equal volume (1 µl) of the oligosaccharide solution, vortexed and
spotted onto a smooth stainless steel plate. The spectra were the
average of 200 scans.1190 PJ Johnson et al
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Localization of O-GalNAc glycosylation sites by
computer analysis
The O-glycosylation sites on the AFP protein core for the linkage
of  O-GalNAc glycans were predicted by a network system,
NetOglyc Version 2.0 (the Center for Biological Sequence
Analysis, accessed via the Internet at http://www.cbs.dtu.dk). This
system can be used to identify mucin O-GalNAc type O-glycosla-
tion sites from a primary protein structure by comparison with data
in O-GLYCBASE, a revised database of O-glycosylated proteins
(Hansen et al, 1995, 1998; Elhammer et al, 1997). The cross-vali-
dated NetOglyc network system correctly found 83%
of the glycosylated and 90% of the non-glycosylated serine and
threonine residues in independent sets of tests.
RESULTS
The 2-AB glycans were first fractionated using reverse-phase
HPLC. Eleven major peak fractions were identified (Figure 2).
The unlabelled peak with an elution time of 45 min was the
unreacted label. Each peak fraction was pooled and the molecular
size was determined by either gel filtration using the
GlycoSequencer or by MALDI-TOF mass spectrometry. All
glycans were desialylated prior to gel filtration and exoglycosidase
sequencing. The experimentally-determined glycan size, the
results of sequential exoglycosidase digestions and the elution
positions of standard sialylated glycans on the reverse phase
column were used to deduce the structures shown in Figure 3.
The relative abundance of the glycans in NSGT sera and HCC
sera is given in Table 1. The difference in abundance of the
glycans between the two groups (percentage for NSGCT glycan
minus percentage for HCC) is presented in Figure 4, ranking the
differences from the largest positive to the largest negative value.
It is evident that the glycan profiles are similar in the sera of the
two tumour types with a slight abundance of G1, G3 and G11 in
NSGCT sera, and of G4, G5 and G7 in HCC sera. No attempt has
been made to subject this conclusion to statistical analysis because
of the small number of observations which still represent a
substantial amount of analytical work.
Table 1 The relative abundance of the 11 major glycans of AFP in NSGCT and HCC
Percentage of total glycan molecules
Glycan G1 G2 G3 G4 G5 G6 G7 G8 G9 G10 G11
NSGCT case 1 5.3 11.7 14.6 9.9 11.3 5.6 1.5 9.9 7.7 11.3 11.3
NSGCT case 2 8.1 18.1 12.8 7.1 13.0 5.0 2.8 6.1 4.5 11.1 11.4
HCC case 1 4.9 14.6 11.4 16.8 19.7 2.4 2.3 6.2 5.2 11.5 5.1
HCC case 2 2.5 14.9 7.9 13.2 13.8 4.7 9.5 8.0 8.6 8.0 9.1
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Figure 2 The reverse phase HPLC chromatogram of 2-AB labelled glycans prepared from HCC AFP. Eleven glycans were identified in the reverse phase
HPLC chromatogram of one of the HCC samples. The glycans were numbered according to the sequence of the corresponding peaks. The unlabelled peak
with an elution time of 45 min was the unreacted label. Similar chromatograms were obtained for the other HCC sample, as well as the two NSCGT samples,
but with different peak heightsGlycan composition of serum AFP 1191
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Glycan composition
All the glycans, except G9, G10 and G11, were treated with siali-
dase. The neutral glycans were injected on the GlycoSequencerTM
in order to obtain information on molecular size. It was apparent
that G3, G6, G7, G8, G9, G10 and G11 are N-linked oligosaccha-
rides having the sizes of larger than or equal to 10 glucose units
(gu) whereas G1, G2 G4 and G5 are small O-linked oligosaccha-
rides having a size of 1 gu or smaller after desialylation.
Composition of N-linked oligosaccharides (G3, G6, G7,
G8, G9, G10 and G11 glycans) – chromatography of
glycan digests
Purified desialylated 2-AB labelled glycans were digested with
b-galactosidase (from Streptococcus pneumoniae). The digests of
individual glycan forms were chromatographed on the Glyco-
SequencerTM. Eluted peaks from several samples were pooled and
digested with b-N-acetylhexosaminidase (from Streptococcus
pneumoniae) and re-chromatographed. Desialylated 2-AB labelled
G3 and G6 glycans initially contained 11.34 gu (Figure 5) and
the size was reduced to 4.8 gu after double digestion, which
corresponds to a Man3GlcNAc2 pentasaccharide core, indicating
that G3 and G6 are bi-antennary complex-type oligosaccharides.
From the elution times of the 2-AB labelled glycans by reverse
phase HPLC it could be concluded that G3 contains two sialic acid
groups and G6 only one.
After the double digestion of G7, G8, G9, G10 and G11 glycans,
a common core polysaccharide of 5.8 gu was identified, corre-
sponding to a FucMan3GlcNAc2 hexasaccharide core. The degree
of sialylation was derived from their elution times by reverse
phase HPLC and it was found that G7 is disialylated, G8 is mono-
sialylated and G9, G10 and G11 are not sialylated.
Further information of the structure of glycans was obtained
from analysing desialylated G3 by MALDI-TOF. Mass spectra of
1783 and 1799 Da were obtained for the sodium and potassium
adducts of G3, identical to their theoretical mass values and
indicating their composition as Hex5HexNAc4-2-AB Na/K. The
mass of sodium and potassium adducts of G10 was found to be
1767 and 1783, respectively, again identical to their theoretical
mass values and indicating their composition as dHex-
Hex4HexNAc4-2-AB Na/K (Figure 5). Among G9, G10 and
G11, the degree of galactosylation was derived from their elution
times by reverse phase HPLC. The MALDI-TOF analysis
indicated that G10 is monogalactosylated. Therefore G9 is
digalactosylated and G11 agalactosylated.
It can be concluded from these investigations that all the
N-linked glycans are biantennary complex-type oligosaccharides,
which differ in the degree of sialylation, fucosylation and galacto-
sylation.
Composition of O-linked oligosaccharides (G1, G2, G4
and G5 glycans) – chromatography of glycan digests
Desialylated G2 glycan could be separated into one minor and one
major component by the GlycoSequencerTM. The minor com-
ponent was identified as D-Galactose by GlycoSepH chroma-
tography. The major component corresponded to 1.01 gu, strongly
indicating its structure as HexHexNAc-AB. The major component
was further digested by b-galactosidase (from bovine testes) and
fractionated by the GlycosequencerTM, which resulted in one
fraction representing undigested material and another fraction
representing a breakdown product. The breakdown product was
identified as D-N-acetylgalactosamine by GlycoSepH chroma-
tography using monosaccharide standards for calibration.
Therefore the major structure of the G2 glycan could be estab-
lished as Galb1®3GalNAc.
The G2 glycan was found to be monosialylated by comparing
the elution times by reverse phase HPLC with that of 2-AB
Figure 3 The structures of the glycans found in HCC and NSGCTs
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labelled 6-sialyl lactosamine. Products of G1 and G2 after siali-
dase digestion had the same elution time at reverse phase HPLC,
which also corresponded to the elution time for G4 glycan.
Therefore G1 is the disialylated form and G2 is the monosialylated
form of the G4 glycan.
The non-digested G5 glycan was identified as a single monosac-
charide of N-acetylhexosamine by GlycoSepH chromatography.
Composition of the 11 glycans
The composition of the 11 glycans, G1–G11, is summarized in
Figure 3.
Identification of potential O-glycosylation sites on AFP
protein core by amino acid sequence analysis
Using the NetOglyc program, which is a software for investigating
protein structures for O-GalNAc glycosylation sites, three threo-
nine residues in positions 132, 208 and 457 of the AFP amino acid
sequence (including the signal peptide region) were identified as
potential sites for O-GalNAc glycosylation. No serine residues
were identified for the O-GalNAc glycosylation (Figure 6).
DISCUSSION
Although AFP has been used as a tumour marker for the diagnosis
of HCC for many years, its specificity is poor when levels fall
within the ‘grey area’, i.e. 10–500 ng ml–1. In this range differen-
tiation between benign and malignant liver diseases cannot be
made with confidence on the basis of serum AFP levels alone.
There is thus a need to find a method of increasing the specificity
of AFP. Recently, using IEF and immunoblotting, various AFP
isoforms appearing as band +II and band +III were found to be
relatively specific for HCC and NSGCT. As the pI value of a
glycoprotein is greatly affected by the degree of glycosylation, it is
important to study the carbohydrate composition of the glycan(s)
carried by AFP before we can elucidate the molecular structure of
the disease-specific isoforms.
In this study we found that the predominant AFP glycans
associated with HCC and NSGCT were mixtures of 11 different
N- and O-linked oligosaccharides. We would acknowledge that the
number of samples was small and in order to gain sufficient mate-
rial for analysis our studies were confined to subjects with very
high total AFP levels. We cannot therefore be certain that our find-
ings are necessarily generalizable to patients with lower AFP
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Figure 5 Two typical examples of the chromatograms obtained in the study. GlycosequencerTM chromatogram of desialylated 2-AB labelled G3 glycan,
indicating a size of 11.3 gu, and MALDI-TOF mass spectrum of GlycoSequencerTM purified 2-AB labelled G10 glycan, indicating sodium and potassium adducts
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levels and we could not analyse directly the AFP arising from
patients with benign liver disease. Similar problems have been
faced by other workers who have attempted direct analytical
studies (Yoshimaet al, 1980; Yamashita et al, 1993; Ferranti et al,
1995). However, the present study is the first to provide direct
information of the glycan composition of serum AFP. Previously,
it has been considered that AFP carries only a single bi-antennary
complex-type  N-glycan, varying in the degree of sialylation,
galactosylation and fucosylation (Yoshima et al, 1980; Yamashita
et al, 1993; Shimizu et al, 1996). We have now demonstrated that
AFP can also carry O-linked glycans.
Some of the structures of N-linked glycans reported in this study
have previously been identified in hepatoblastoma cell lines, cord
serum and tumour ascitic fluid (Yoshima et al, 1980; Yamashita
et al, 1993; Ferranti et al, 1995). Seven N-linked glycans found
in this study were composed of the typical GlcNAc2Man3GlcNAc2
N-linked heptasaccharide core, with different degrees of sialyla-
tion, fucosylation and galactosylation. The G10 (asialo mono-
galacto) glycan and G11 (asialo agalacto) glycan are two sugar
chains of AFP not previously reported, although the presence of
serum AFP isoforms with different degrees of galactosylation has
been suggested indirectly by a study using sequential exoglycosi-
Figure 6 NetOglyc 2.0 Prediction Results. The potential O-GalNAc glycosylation sites (T) are indicated correspondingly.1194 PJ Johnson et al
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dase digestion and lectin affinity electrophoresis (Shimizu et al,
1996).
Previous reports have suggested that AFP glycoforms in HCC
and NSGCT carry tri-antennary or N-acetylglucosaminylated
bi-antennary carbohydrate structures making them non-reactive to
ConA (Yamashita et al, 1983; Aoyagi et al, 1991). Yamashita et al
(1983) identified acetylglucosaminylated bi-antennary N-glycans
in AFP purified from human yolk sac tumours grown in nude mice
in support of this proposal. Neither tri-antennary nor acetyl-
glucosaminylated bi-antennary N-glycans were found in our study.
There are several possibilities to account for such differences.
Firstly, the glycosylation mechanisms may have changed during
the growth of the human yolk sac tumour in nude mice. Secondly,
AFP with tri-antennary or acetylglucosaminylated bi-antennary
N-glycans may not be released into the blood circulation, or may
have a short half-life in the circulation. Thirdly, tri-antennary or
acetylglucosaminylated bi-antennary N-glycans could still have
been present in our samples but in amounts below our detection
limit for the method used.
The identification of AFP with O-linked glycans is a surprising
finding as several previous investigators should have detected
these isoforms (Yoshima et al, 1980; Yamashita et al, 1983,
1993; Aoyagi et al, 1991). Under different experimental condi-
tions, O-linked and N-linked glycans can be differentially released
from proteins by hydrazinolysis (Patel et al, 1993). Therefore
differences in our conditions (aimed to release both the O-linked
and  N-linked glycans) compared to those used in the previous
investigations may explain the previous negative results. Three
(G1, G2 and G4) of the four identified O-linked glycans in
our study are of mucin type, composed of the typical
Galb1®3GalNAc  O-linked disaccharide core, with different
degrees of sialylation. This conclusion is independently supported
by computer analysis of the primary protein structure of AFP,
which predicts the presence of three potential O-GalNAc
glycosylation sites for mucin O-GalNAc type O-glycans. For
the O-HexNAc monosaccharide glycan (G5), characterization
experiments are continuing in our laboratories.
The distribution of the different glycans linked to AFP is quite
similar in sera from patients with NSGCT and HCC. There is a
slightly higher abundance of the G1, G3 and G11 glycans in
NSGCT AFP and of the G4, G5 and G7 glycans in HCC AFP.
Although the number of observations is small, this difference is
noteworthy and will be subjected to further studies. The G3 and
G7 glycans are of the N-linked disialylated bi-antennary complex-
type, but only the latter has an additional proximal fucose. A
higher abundance of G7 in HCC AFP suggests that fucosylation of
AFP is more pronounced in HCC. In support of this conclusion is
the finding that lentil lectin-reactive AFP – a proposed diagnostic
marker for HCC and not for benign liver disease – appears to
be those AFP glycoforms carrying fucosylated N-glycans (Du et
al, 1991; Taketa et al, 1993; Shimizu et al, 1996).
The G1, G4 and G5 glycans are O-linked, but the former is
disialylated and latter two asialylated. We cannot, at the present
time, explain why there should exist an abundance of the G1
glycan in NSGCT AFP, and of the G4 and G5 glycan in HCC AFP.
The higher abundance of the G11 glycan in NSGCT AFP may help
to explain why the AFP +III (band +III) appears as the specific
isoform for NSGCTs (Johnson et al, 1995). The G11 glycan is
asialylated, and the attachment of a G11 glycan (asialylated)
instead of a G3 or G7 glycan (disialylated) to the AFP protein core
should result in the formation of a more basic isoform.
In conclusion, the present data clearly show that besides
bi-antennary complex-type N-glycans, there are also O-linked
glycans on serum AFP in HCC and NSGCT. The use of the
NetOglyc network system for the prediction of O-GalNAc
glycosylation sites on AFP is a good example of using molecular
modelling to support laboratory findings.
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